| 36656599 | Assessing-and Extending-California's Insulin Manufacturing Initiative. | JAMA | 2023 |
| 34914166 | Preprint servers and patent prior art: Preprints can jeopardize the patentability of an invention: Preprints can jeopardize the patentability of an invention. | EMBO Rep | 2022 |
| 37928339 | FAMILIAL SEARCHES, THE FOURTH AMENDMENT, AND GENOMIC CONTROL. | South Calif Law Rev | 2022 |
| 35476355 | Handle with Care: The WHO Report on Human Genome Editing. | Hastings Cent Rep | 2022 |
| 35438517 | Immaculate Conception? Priority and Invention in the CRISPR Patent Dispute. | CRISPR J | 2022 |
| 35042809 | Ethical, legal, and social issues in the Earth BioGenome Project. | Proc Natl Acad Sci U S A | 2022 |
| 35042800 | The Earth BioGenome Project 2020: Starting the clock. | Proc Natl Acad Sci U S A | 2022 |
| 34113035 | Voices of biotech leaders. | Nat Biotechnol | 2021 |
| 35557745 | Governance Choices of Genome Editing Patents. | Front Polit Sci | 2021 |
| 34459849 | Governing Human Germline Editing Through Patent Law. | JAMA | 2021 |
| 34037521 | Biological controls for standardization and interpretation of adaptive immune receptor repertoire profiling. | Elife | 2021 |
| 32151165 | Models of Technology Transfer for Genome-Editing Technologies. | Annu Rev Genomics Hum Genet | 2020 |
| 33095048 | Reactions to the National Academies/Royal Society Report on <i>Heritable Human Genome Editing</i>. | CRISPR J | 2020 |
| 32943452 | Self-experimentation, ethics, and regulation of vaccines. | Science | 2020 |
| 32887962 | The FDA De Novo medical device pathway, patents and anticompetition. | Nat Biotechnol | 2020 |
| 33021166 | Gene Editing Sperm and Eggs (not Embryos): Does it Make a Legal or Ethical Difference? | J Law Med Ethics | 2020 |
| 30936866 | Inferred Allelic Variants of Immunoglobulin Receptor Genes: A System for Their Evaluation, Documentation, and Naming. | Front Immunol | 2019 |
| 31273115 | Regulating genetic biohacking. | Science | 2019 |
| 31321802 | Patent Eligibility Reform and the Public Health. | Milbank Q | 2019 |
| 31599678 | Controlling CRISPR Through Law: Legal Regimes as Precautionary Principles. | CRISPR J | 2019 |
| 29608656 | Fortune and hindsight: gene patents' muted effect on medical practice. | Br Med Bull | 2018 |
| 31143463 | Is it 'gene therapy'? | J Law Biosci | 2018 |
| 31021275 | The CRISPR-Cas9 Patent Appeal: Where Do We Go From Here? | CRISPR J | 2018 |
| 31021185 | The CRISPR Patent Landscape: Past, Present, and Future. | CRISPR J | 2018 |
| 28072792 | The rise of the ethical license. | Nat Biotechnol | 2017 |
| 29868185 | Patent protection for CRISPR: an ELSI review. | J Law Biosci | 2017 |
| 28336632 | Patent pools for CRISPR technology-Response. | Science | 2017 |
| 28209863 | CRISPR, surrogate licensing, and scientific discovery. | Science | 2017 |
| 28117563 | Patent Law's Reproducibility Paradox. | Duke Law J | 2017 |
| 29259531 | CRISPR, Patents, and the Public Health. | Yale J Biol Med | 2017 |
| 29029027 | Patent protection for microbial technologies. | FEMS Microbiol Lett | 2017 |
| 28946923 | Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic. | Genome Med | 2017 |
| 28536246 | Inventive steps: the CRISPR patent dispute and scientific progress: The recent patent decisions about CRISPR tell us a lot about how advances in biology are actually made-and how they are not. | EMBO Rep | 2017 |
| 27075081 | CRISPR: Pursuit of profit poisons collaboration. | Nature | 2016 |
| 27153268 | Protecting products versus platforms. | Nat Biotechnol | 2016 |
| 26963552 | The changing life science patent landscape. | Nat Biotechnol | 2016 |
| 25748913 | Law, history and lessons in the CRISPR patent conflict. | Nat Biotechnol | 2015 |
| 26442843 | The History of Patenting Genetic Material. | Annu Rev Genet | 2015 |
| 25957901 | Stem cell patents after the america invents act. | Cell Stem Cell | 2015 |
| 24535082 | 23andMe, the Food and Drug Administration, and the future of genetic testing. | JAMA Intern Med | 2014 |
| 25004225 | Myriad stands alone. | Nat Biotechnol | 2014 |
| 23563426 | Federal Trade Commission v. Actavis, Inc. and reverse-payment or pay-for-delay settlements. | Nat Biotechnol | 2013 |
| 23559235 | Genomics. What if extinction is not forever? | Science | 2013 |
| 23896757 | The future of gene patents and the implications for medicine. | JAMA Intern Med | 2013 |